Molecular Formula	C25H29I2NO3
Molecular Weight	645.3
Structure
State	solid
Clearance	* 90-158 mL/h/kg [Healthy with a single dose IV (5 mg/kg over 15 min)] * 100 mL/h/kg [Normal subjects > 65 yrs] * 150 mL/h/kg [younger subjects] * 220 and 440 mL/h/kg [patients with VT and VF]
Route of elimination	Amiodarone is eliminated primarily by hepatic metabolism and biliary excretion and there is negligible excretion of amiodarone or DEA in urine.
Protein binding	>96%
Half life	58 days (range 15-142 days)
Absorption	Slow and variable (about 20 to 55% of an oral dose is absorbed).
Trade names	Cordarone, Nexterone
Description	anti-arrhythmic drug

Toxicity	Dose	Time	Species	Model	Method	Action	Positive criterion	Reference
OPENING OF PERMEABILITY TRANSITION PORE (PTP)	10 µM	1 hour	Human	HepG2	High-content screening assay	Increase	MEC	306
UNCOUPLING	1 μmol/L		rat; Sprague–Dawley	hepatocytes	Measurement of oxygen uptake	Negative	p < 0.05	4
UNCOUPLING	10 μmol/L		rat; Sprague–Dawley	hepatocytes	Measurement of oxygen uptake	Negative	p < 0.05	4
UNCOUPLING	20 μmol/L		rat; Sprague–Dawley	hepatocytes	Measurement of oxygen uptake	Negative	p < 0.05	4
UNCOUPLING	50 μmol/L		rat; Sprague–Dawley	hepatocytes	Measurement of oxygen uptake	Negative	p < 0.05	4
UNCOUPLING	80 μmol/L		rat; Sprague–Dawley	hepatocytes	Measurement of oxygen uptake	Negative	p < 0.05	4
UNCOUPLING	100 μmol/L		rat; Sprague–Dawley	hepatocytes	Measurement of oxygen uptake	affect	p < 0.01	4
ELECTROPHORETIC UNCOUPLING								278
MEMBRANE POTENTIAL	0.5 μmol/L	1 hour	rat; Sprague–Dawley	hepatocytes	Measurement of mitochondrial membrane potential	Negative	p < 0.05	4
MEMBRANE POTENTIAL	1 μmol/L	1 hour	rat; Sprague–Dawley	hepatocytes	Measurement of mitochondrial membrane potential	Negative	p < 0.05	4
MEMBRANE POTENTIAL	4 μmol/L	1 hour	rat; Sprague–Dawley	hepatocytes	Measurement of mitochondrial membrane potential	Negative	p < 0.05	4
MEMBRANE POTENTIAL	8 μmol/L	1 hour	rat; Sprague–Dawley	hepatocytes	Measurement of mitochondrial membrane potential	decrease	p < 0.05	4
MEMBRANE POTENTIAL	20 μmol/L	1 hour	rat; Sprague–Dawley	hepatocytes	Measurement of mitochondrial membrane potential	decrease	p < 0.01	4
MEMBRANE POTENTIAL	2.6 µM	30 mins	mouse	liver mitochondria	Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss)	decrease	EC20	36
MEMBRANE POTENTIAL	50 µM	1 hour	Human	HepG2	High-content screening assay	Decrease	MEC	306
MEMBRANE POTENTIAL	5 µM	1 hour	Human	HepG2	High-content screening assay	Increase	MEC	306
RESPIRATION	45.92 µM	60 mins	mouse	liver mitochondria	Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition.	decrease	EC20	36
RESPIRATION	ND	60 mins	mouse	liver mitochondria	Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition.	Negative	EC20	36
STATE 3 RESPIRATION	10 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	Negative	p < 0.05	4
STATE 3 RESPIRATION	20 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	Negative	p < 0.05	4
STATE 3 RESPIRATION	50 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	Negative	p < 0.05	4
STATE 3 RESPIRATION	100 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	decrease	p < 0.01	4
STATE 3 RESPIRATION	10 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	Negative	p < 0.05	4
STATE 3 RESPIRATION	20 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	Negative	p < 0.05	4
STATE 3 RESPIRATION	50 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	Negative	p < 0.05	4
STATE 3 RESPIRATION	100 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	Negative	p < 0.05	4
RESPIRATORY CONTROL RATIO (RCR)	10 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	decrease	p < 0.01	4
RESPIRATORY CONTROL RATIO (RCR)	20 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	decrease	p < 0.01	4
RESPIRATORY CONTROL RATIO (RCR)	50 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	decrease	p < 0.01	4
RESPIRATORY CONTROL RATIO (RCR)	100 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	decrease	p < 0.01	4
RESPIRATORY CONTROL RATIO (RCR)	10 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	decrease	p < 0.01	4
RESPIRATORY CONTROL RATIO (RCR)	20 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	decrease	p < 0.01	4
RESPIRATORY CONTROL RATIO (RCR)	50 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	decrease	p < 0.01	4
RESPIRATORY CONTROL RATIO (RCR)	100 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of oxygen uptake	decrease	p < 0.01	4
ELECTRON TRANSPORT CHAIN	50 μM		bovine	heart mitochondria	Measurement of complex I activity	decrease	p < 0.05	3
ELECTRON TRANSPORT CHAIN	50 μM		bovine	heart mitochondria	Measurement of complex II + III activity	decrease	p < 0.001	3
ELECTRON TRANSPORT CHAIN	50 μM		bovine	heart mitochondria	Measurement of complex II + III activity	decrease	p < 0.001	3
ELECTRON TRANSPORT CHAIN	50 μM		bovine	heart mitochondria	Measurement of complex IV activity	decrease	p < 0.05	3
ELECTRON TRANSPORT CHAIN	50 μM		bovine	heart mitochondria	Measurement of complex V activity	decrease	p < 0.001	3
ELECTRON TRANSPORT CHAIN						decrease		36
GLUCOSE GALACTOSE IC50 RATIO	75.2 ± 12.9, 92.0 ± 5.5, 0.8, 95.1 ± 10.1 ,69.1 ± 24.1, 1.3	4hr		H9c2 cells	high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ).		glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla )	50
FATTY ACID METABOLISM	20µM	24hr		isolated rat liver mitochondria, and the human hepatoma cell line HepG2		inhibit		271
MITOCHONDRIAL FATTY ACID BETA OXIDATION	10 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of beta oxidation and ketone body formation	Negative	p < 0.05	4
MITOCHONDRIAL FATTY ACID BETA OXIDATION	20 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of beta oxidation and ketone body formation	decrease	p < 0.01	4
MITOCHONDRIAL FATTY ACID BETA OXIDATION	50 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of beta oxidation and ketone body formation	decrease	p < 0.01	4
MITOCHONDRIAL FATTY ACID BETA OXIDATION	80 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of beta oxidation and ketone body formation	decrease	p < 0.01	4
MITOCHONDRIAL FATTY ACID BETA OXIDATION	100 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of beta oxidation and ketone body formation	decrease	p < 0.01	4
MITOCHONDRIAL FATTY ACID BETA OXIDATION	100 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of acyl‐CoA dehydrogenase activity	decrease	28% inhibition	4
MITOCHONDRIAL FATTY ACID BETA OXIDATION	100 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of β‐ketothiolase activity	Negative	no inhibition	4
MITOCHONDRIAL FATTY ACID BETA OXIDATION						affect		227
MITOCHONDRIAL FATTY ACID BETA OXIDATION	228 μmol/L		rat	cardiac and hepatic mitochondria	CPT-1 activity was measured by the formation of palmitoyl-[3H]-carnitine from palmitoyl-CoA and [3H]-I- carnitine,	affect	IC50	240
MITOCHONDRIAL FATTY ACID BETA OXIDATION	28.5/>100		human/rat	hepatocytes	Fatty acid oxidation (FAO) was determined by measuring 14CO2 release from 14C-labeled palmitate	inhibition	IC50 (μM)	333
SYNTHESIS OF KETONE BODY	34 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of beta oxidation and ketone body formation	decrease	IC50	4
SYNTHESIS OF KETONE BODY	16.6		Wistar rat	hepatocytes	ketone bodies (KB = β-hydroxybutyrate + acetoacetate) were determined with a commercially available kit (Autokit 3-HB from Wako)	inhibition	IC50 (μM)	333
SWELLING	1 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurements of mitochondrial swelling	Negative	p < 0.05	4
SWELLING	10 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurements of mitochondrial swelling	Negative	p < 0.05	4
SWELLING	100 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurements of mitochondrial swelling	increase	p < 0.05	4
SWELLING	ND	30 mins	mouse	liver mitochondria	swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling )	Negative	EC20	36
OXIDATIVE STRESS	0.1 μmol/L	1 hour	human	HepG2	Measurement of ROS	Negative	p < 0.05	4
OXIDATIVE STRESS	1 μmol/L	1 hour	human	HepG2	Measurement of ROS	increase	p < 0.05	4
OXIDATIVE STRESS	100 μmol/L	1 hour	human	HepG2	Measurement of ROS	increase	p < 0.05	4
OXIDATIVE STRESS								185
ROS PRODUCTION	10 µM	1 hour	Human	HepG2	High-content screening assay	Increase	MEC	306
APOPTOSIS	100 μmol/L	8 hours	human	HepG2	Assessment of cytochrome c release	increase	observable	4
LATE APOPTOSIS	100 μmol/L	8 hours	rat; Sprague–Dawley	hepatocytes	Apoptosis measurement	increase	p < 0.01	4
LATE APOPTOSIS	1 μmol/L	8 hours	rat; Sprague–Dawley	hepatocytes	Apoptosis measurement	Negative	p < 0.05	4
LATE APOPTOSIS	100 μmol/L	8 hours	rat; Sprague–Dawley	hepatocytes	Apoptosis measurement	increase	p < 0.05	4

Target	Dose	Time	Species	Model	Method	Action	Positive criterion	Reference
NADH:ubiquinone reductase	50 μM		bovine	heart mitochondria	Measurement of complex I activity	inhibitor	p < 0.05	3
NADH:ubiquinone reductase						inhibitor		36
NADH:ubiquinone reductase	45.92 µM	60 mins	mouse	liver mitochondria	Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition.	inhibit	EC20	36
Succinate dehydrogenase	50 μM		bovine	heart mitochondria	Measurement of complex II + III activity	inhibitor	p < 0.001	3
Succinate dehydrogenase	ND	60 mins	mouse	liver mitochondria	Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition.	Negative	EC20	36
Quinol--cytochrome-c reductase	50 μM		bovine	heart mitochondria	Measurement of complex II + III activity	inhibitor	p < 0.001	3
Cytochrome c oxidase	50 μM		bovine	heart mitochondria	Measurement of complex IV activity	inhibitor	p < 0.05	3
ATP synthase	50 μM		bovine	heart mitochondria	Measurement of complex V activity	inhibitor	p < 0.001	3
carnitine palmitoyltransferases I						inhibit		227
carnitine palmitoyltransferases I	228 μmol/L		rat	cardiac and hepatic mitochondria	CPT-1 activity was measured by the formation of palmitoyl-[3H]-carnitine from palmitoyl-CoA and [3H]-I- carnitine,	inhibit	IC50	240
Carnitine O-palmitoyltransferase 1, liver isoform, CPT1-L, EC 2.3.1.21	>100/−		human/rat	recombinant Pichia pastoris Membrane Preparations	spectrophotometric assay with DTNB	Negative	IC50 (μM)	333
Carnitine O-palmitoyltransferase 1, muscle isoform	>100		human/rat	recombinant Pichia pastoris Membrane Preparations	spectrophotometric assay with DTNB	Negative	IC50 (μM)	333
Carnitine O-palmitoyltransferase 2, mitochondrial, EC 2.3.1.21	>100/−		human/rat	recombinant Pichia pastoris Membrane Preparations	spectrophotometric assay with DTNB	Negative	IC50 (μM)	333
3-ketoacyl-CoA thiolase, mitochondrial	100 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of β‐ketothiolase activity	Negative	no inhibition	4
Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial	100 μmol/L		rat; Sprague–Dawley	liver mitochondria	Measurement of acyl‐CoA dehydrogenase activity	inhibitor	28% inhibition	4
Reactive oxygen species	10 µM	1 hour	Human	HepG2	High-content screening assay	increase	MEC	306
Cytochrome c	100 μmol/L	8 hours	human	HepG2	Assessment of cytochrome c release	release	observable	4
Cytochrome c	< 50 µM	30 mins	mouse	liver mitochondria	Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline)	release	EC20	36

Organism	Test type	Route	Dose (normalized dose)	Effect	Source
mouse	LD50	oral	> 3gm/kg (3000mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992.
mouse	LD50	intraperitoneal	450mg/kg (450mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992.
man	TDLo	unreported	57mg/kg/5D-I (57mg/kg)	cardiac: pulse rate increase without fall in bp	Annals of Internal Medicine. Vol. 97, Pg. 561, 1982.
women	TDLo	multiple routes	1475mg/kg/7W- (1475mg/kg)	cardiac: other changes	American Journal of Cardiology. Vol. 58, Pg. 1110, 1986.
women	TDLo	intravenous	3mg/kg (3mg/kg)	brain and coverings: increased intracranial pressure	Critical Care Medicine. Vol. 13, Pg. 688, 1985.
man	TDLo	unreported	51mg/kg/6D-C (51mg/kg)	skin and appendages (skin): "dermatitis, other: after systemic exposure"	British Medical Journal. Vol. 296, Pg. 1322, 1988.
child	LDLo	oral	568mg/kg/9W-I (568mg/kg)		Journal of Pediatrics. Vol. 107, Pg. 967, 1985.
women	TDLo	oral	2480mg/kg/43W (2480mg/kg)	endocrine: thyroid weight (goiter)	Acta Medica Scandinavica. Vol. 221, Pg. 219, 1987.
rat	LD50	intraperitoneal	610mg/kg (610mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992.
man	LDLo	oral	2086mg/kg/2Y- (2086mg/kg)		Netherlands Journal of Medicine. Vol. 29, Pg. 303, 1986.
dog	LD50	oral	> 5gm/kg (5000mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992.
man	TDLo	intravenous	26mg/kg/1D-C (26mg/kg)		American Heart Journal. Vol. 131, Pg. 1214, 1996.
women	TDLo	oral	1128mg/kg/56W (1128mg/kg)		American Journal of Medicine. Vol. 86, Pg. 134, 1989.
women	TDLo	oral	64mg/kg/4D-I (64mg/kg)		Lancet. Vol. 350, Pg. 1300, 1997.
women	TDLo	unreported	48mg/kg/3D-I (48mg/kg)	cardiac: pulse rate increase without fall in bp	American Heart Journal. Vol. 130, Pg. 399, 1995.
dog	LD50	intravenous	5gm/kg (5000mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992.
women	TDLo	oral	416mg/kg/30D- (416mg/kg)	lungs, thorax, or respiration: other changes	Archives of Internal Medicine. Vol. 147, Pg. 50, 1987.
man	TDLo	oral	133mg/kg/23D- (133mg/kg)	skin and appendages (skin): photosensitivity: after systemic exposure	Lancet. Vol. 1, Pg. 51, 1984.
rat	LD50	oral	> 3gm/kg (3000mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992.
mouse	LD50	oral	> 4gm/kg (4000mg/kg)		European Patent Application. Vol. #0076973,
man	TDLo	oral	171mg/kg/30D- (171mg/kg)		American Heart Journal. Vol. 100, Pg. 412, 1980.
man	LDLo	unreported	3650mg/kg/3.5 (3650mg/kg)		Clinical Endocrinology Vol. 45, Pg. 365, 1996.
man	LDLo	oral	3129mg/kg/3Y- (3129mg/kg)		Southern Medical Journal. Vol. 89, Pg. 85, 1996.
man	TDLo	oral	1714mg/kg/21W (1714mg/kg)		New England Journal of Medicine. Vol. 308, Pg. 779, 1983.
rat	LD50	intraperitoneal	885mg/kg (885mg/kg)		European Patent Application. Vol. #0076973,
women	TDLo	oral	120mg/kg/10D- (120mg/kg)	cardiac: arrhythmias (including changes in conduction)	Human Toxicology. Vol. 4, Pg. 169, 1985.
man	LDLo	oral	1869mg/kg/22W (1869mg/kg)		American Journal of Medicine. Vol. 77, Pg. 751, 1984.
women	TDLo	oral	5200mg/kg/5Y- (5200mg/kg)		Respiration. Vol. 49, Pg. 157, 1986.
women	TDLo	oral	5796mg/kg/69W (5796mg/kg)		Italian Journal of Neurological Sciences. Vol. 8, Pg. 605, 1987.
man	TDLo	oral	240mg/kg/6W-I (240mg/kg)	skin and appendages (skin): hair: other	Archives of Internal Medicine. Vol. 155, Pg. 1106, 1995.
rat	LD50	intravenous	170mg/kg (170mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992.
man	TDLo	oral	3651mg/kg/2.3 (3651mg/kg)		American Journal of Gastroenterology. Vol. 83, Pg. 161, 1988.
man	TDLo	oral	60mg/kg/2W-I (60mg/kg)		Chest. Vol. 88, Pg. 630, 1985.
man	TDLo	oral	390mg/kg/39W- (390mg/kg)		Netherlands Journal of Medicine. Vol. 42, Pg. 21, 1993.
mouse	LD50	intraperitoneal	254mg/kg (254mg/kg)		European Journal of Toxicology and Environmental Hygiene. Vol. 8, Pg. 122, 1975.
mouse	LD50	intravenous	178mg/kg (178mg/kg)		European Journal of Toxicology and Environmental Hygiene. Vol. 8, Pg. 188, 1975.
women	TDLo	intravenous	36mg/kg/1D-I (36mg/kg)	endocrine: evidence of thyroid hyperfunction	Israel Journal of Medical Sciences. Vol. 21, Pg. 165, 1985.
man	TDLo	intravenous	4286ug/kg (4.286mg/kg)	brain and coverings: increased intracranial pressure	Critical Care Medicine. Vol. 13, Pg. 688, 1985.

Agitation

Arrhythmia

Asthma

Atrial fibrillation

Drug interaction

Hyperkinesia

Pulmonary fibrosis

Respiratory failure

Sinus arrhythmia

Sudden death

Tachyarrhythmia

Ventricular arrhythmia

Ventricular tachycardia

Wolff-Parkinson-White syndrome

Cardiogenic shock (0.01)

Alanine aminotransferase increased

Aspartate aminotransferase increased

Atrial fibrillation

Atrioventricular block

Body temperature increased

Bradycardia

Cardiac arrest

Cardiac failure congestive

Diarrhoea

Electrocardiogram QT prolonged

Hypotension

Liver function test abnormal

Nausea

Nodal arrhythmia

Pulmonary oedema

Renal impairment

Shock

Thrombocytopenia

Ventricular fibrillation

Ventricular tachycardia

Vomiting

(2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone	(2-Butyl-benzofuran-3-yl)(4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl)methanone #	(2-Butylbenzofuran-3-yl)(4-(2-(diethylamino)-ethoxy)-3,5-diiodophenyl)methanone
(2-Butylbenzofuran-3-yl)(4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl)methanone	(2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone	(2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodophenyl]methanone
(2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone	(2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone	(2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodo-phenyl]methanone
(2-n-butyl-3-benzofuranyl) [4-[2-(diethylamino)ethoxyl]-3,5-diiodophenyl] methanone	(2-n-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxyl]-3,5-diiodophenyl]methanone	(2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine
1951-25-3	2-Butyl-3-(3,5-diiodo-4-(.beta.-diethylaminoethoxy)benzoyl)benzofuran	2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran
2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran	2-Butyl-3-(4'-.beta.-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran	2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran
2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone	2-Butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl ketone	2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone
2-Butyl-3-benzofuranyl-4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl ketone	2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran	20514-EP2272832A1
20514-EP2305668A1	20514-EP2314585A1	4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl 2-butylbenzo[b]furan-3-yl ketone
5-18-02-00353 (Beilstein Handbook Reference)	951A253	AB00053422
AB00053422-17	AB00053422_18	AB00053422_19
AKOS005462717	API0001453	AX8114028
Amidorone	Amiodarona	Amiodarona [INN-Spanish]
Amiodarone (USAN/INN)	Amiodarone Base	Amiodarone [USAN:BAN:INN]
Amiodarone [USAN:INN:BAN]	AmiodaroneHCl	Amiodaronum
Amiodaronum [INN-Latin]	Amjodaronum	Atlansil
BBI	BDBM18957	BIDD:GT0425
BIDD:PXR0146	BPBio1_000372	BRD-K17561142-003-16-8
BRN 1271711	BSPBio_000338	BSPBio_001574
BSPBio_002580	Bio1_000026	Bio1_000515
Bio1_001004	Bio2_000294	Bio2_000774
C-23400	C06823	C25H29I2NO3
CAS-1951-25-3	CAS-19774-82-4	CBiol_001740
CC-24083	CCG-204217	CCRIS 9360
CHEBI:2663	CHEMBL633	CS-2834
CTK4G7797	Cordarone	Cordarone (Salt/Mix)
Cyto8E2	D02910	DB01118
DSSTox_CID_2592	DSSTox_GSID_22592	DSSTox_RID_76649
DTXSID7022592	DivK1c_000079	EINECS 217-772-1
F2173-1018	FT-0601533	GTPL2566
HMS1791O16	HMS1989O16	HMS2089C07
HY-14187	IDI1_000079	IDI1_034044
IYIKLHRQXLHMJQ-UHFFFAOYSA-N	KBio1_000079	KBio2_000294
KBio2_000741	KBio2_002862	KBio2_003309
KBio2_005430	KBio2_005877	KBio3_000587
KBio3_000588	KBio3_001800	KBioGR_000294
KBioGR_001859	KBioSS_000294	KBioSS_000741
Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl	Kordaron	L 3428
L-3428	L001174	LS-87088
Labaz (Salt/Mix)	Lopac-A-8423	Lopac0_000122
MCULE-4156227717	Methanone, (2-butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl)-	Methanone, (2-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]-
Methanone,(2-butyl-3-benzofuranyl)[4-[2-(diethyloxidoamino)ethoxy]-3,5-diiodophenyl]-	N3RQ532IUT	NCGC00015096-01
NCGC00015096-02	NCGC00015096-03	NCGC00015096-04
NCGC00015096-05	NCGC00015096-06	NCGC00015096-07
NCGC00015096-08	NCGC00015096-09	NCGC00015096-10
NCGC00015096-11	NCGC00015096-12	NCGC00015096-13
NCGC00015096-14	NCGC00015096-17	NCGC00024242-03
NCGC00024242-04	NCGC00024242-05	NCGC00024242-06
NCI60_041885	NINDS_000079	Pacerone
Prestwick0_000409	Prestwick1_000409	Prestwick2_000409
Prestwick3_000409	Q410061	QTL1_000008
SBI-0050110.P003	SC-18813	SCHEMBL16284
SKF 33134-A	SKF-33134-A (Salt/Mix)	SKF-33134A
SPBio_001825	SPBio_002277	ST51014902
STK529812	Spectrum2_001813	Spectrum3_001050
Spectrum4_001190	Spectrum5_001533	Spectrum_000261
Tox21_110083	Tox21_110083_1	Tranquerone
UNII-N3RQ532IUT	UNM000001215003	W-107695
ZINC3830212	amiodarone	cid_441325

DrugBank Name	Amiodarone
DrugBank	DB01118
CAS Number	1951-25-3, 19774-82-4, 318267-30-0
PubChem Compound	2157
KEGG Compound ID	C06823
KEGG Drug	D02910
PubChem.Substance	46507387
ChEBI	2663
PharmGKB	PA448383
ChemSpider	2072
BindingDB	18957.0
TTD	DAP000496
Wikipedia	Amiodarone
HET	BBI
DPD	1400